The United Kingdom and the United States have agreed to a landmark bilateral deal that will ensure no tariffs on UK medicine exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the public health system. This commitment ensures that tariffs on these key products will be held at nothing for a period of three years.
This agreement comes after previous statements to dramatically increase import taxes on patented pharmaceutical imports, with figures floated reaching 100%.
"This agreement between the Britain strengthens the international landscape for innovative medicines and establishes long-overdue equity to American-British pharmaceutical trade," an announcement noted.
Trade Importance
Drugs constitute one of the UK's biggest export categories to the America, which is easily the largest market for large British pharmaceutical firms.
Export figures indicate that in the year leading up to the third quarter, the UK exported medicines valued at billions to the US. This value made up a significant portion of total UK exports in that period.
"This deal safeguards jobs, boosts funding and facilitates the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement entails several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to double overall NHS spending on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Last year, rebates exceeded 20%.
Broader Context
The deal comes amid a long-running row between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
These tensions were heightened by assertions that American patients were paying a premium for the identical medicines than consumers in the other developed nations.
Recently, several major drug company projects in the UK have been halted or abandoned, while major expansions have been pledged toward projects in the United States.
A senior figure stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
